MedTrace Logo

Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

NCT01256580 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-01-14

No results posted yet for this study

Summary

Anti-VEGF therapy has been proven efficacious for the wet (neovascular) form of macular degeneration and may be beneficial for the treatment of choroidal neovascularization (CNV) due to other causes. The limitation of this type of treatment is the necessity for frequent intraocular injections. The purpose of this study is to determine if using anti-VEGF therapy in combination with photodynamic therapy can reduce the number of treatments needed with monotherapy while achieving similar visual results. There are ongoing multicenter trials evaluating combination therapy in patients with wet AMD but no similar trial for patients with CNV due to non-AMD causes. Therefore, in this study the investigators will focus on patients with CNV not due to AMD.

Conditions

  • Choroidal Neovascularization
  • Myopia
  • Punctate Inner Choroidopathy (PIC)
  • Multifocal Choroiditis
  • Ocular Histoplasmosis Syndrome
  • Central Serous Chorioretinopathy (CSC)
  • Angioid Streaks
  • Trauma, or Hereditary Eye Diseases

Interventions

DRUG

Bevacizumab (Avastin; Genentech, Inc.)

1.25 mg bevacizumab (Avastin; Genentech, Inc.) by intravitreal injection

DRUG

Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy

Intravitreal injection of 1.25 mg bevacizumab (Avastin; Genentech, Inc.) combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis) and 200ug of intravitreal dexamethasone

Sponsors & Collaborators

  • Massachusetts Eye and Ear Infirmary

    lead OTHER

Principal Investigators

  • Ivana K Kim, MD · Massachussetts Eye& Ear Infirmary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2013-03-31
Completion
2013-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01256580 on ClinicalTrials.gov